What Melanoma Patients Need to Know About AMTAGVI

By Renee Orcione, MRA Digital Engagement & Communications Manager | 28 March 2024 In News, Science, Treatment

You may have heard of AMTAGVI, also known by the generic name lifileucel, a new therapy that recently earned FDA approval. AMTAGVI is a type of cellular therapy that uses Tumor Infiltrating Lymphocytes (TILs) to treat patients with advanced melanoma whose melanoma hasn’t responded – or quit responding – to PD-1 based immunotherapies and BRAF/MEK targeted therapy if their melanoma has the BRAF mutation.

Read More

Melanoma Research Alliance and Antidote Improve the Clinical Trial Navigator Experience for Patients and Caregivers

By Renee Orcione, MRA Digital Engagement & Communications Manager | 26 March 2024 In Allies & Partnerships, Science, Treatment

In an effort to empower and assist melanoma patients in their clinical trial search, MRA first joined forces with Antidote in 2017 to provide a streamlined, easy-to-use clinical trial search tool. Recently, we launched a major update to the tool with enhancements to make searches more patient-centric, especially for individuals who are impacted by rare melanoma subtypes and those seeking systemic therapy at earlier stages of disease.

Read More

Overcoming Melanoma and Finding Purpose: Brittanny Groover's Story

By Renee Orcione, MRA Digital Engagement & Communications Manager | 21 March 2024 In Allies & Partnerships, Melanoma Stories, Prevention, Treatment

Growing up as a child in the 2000s and even later into her teens and early 20s, Brittanny Groover wanted what many other young girls and women want: to be tan. Whether it was using tanning beds with her high school friends or laying out by the pool with her...

Read More

The Future of Immunotherapy & Cell-based Therapies

11 March 2024 In Allies & Partnerships, Events, News, Science, Treatment

“Melanoma research helped lead the way to a lot of paradigm shifts in cancer treatment,” says Dr. Antoni Ribas, Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). 

Read More

Toni English's Journey from Mucosal Melanoma Patient to Advocate

By Renee Orcione, MRA Digital Engagement & Communications Manager | 28 February 2024 In Allies & Partnerships, Melanoma Stories, Science, Treatment

In the five years since overcoming Stage 4 mucosal melanoma, Toni English has found her life’s passion advocating for patients and families and championing research to answer the many questions that surround this rare melanoma.

Read More

Recordings from MRA's 2024 Patient Forum

27 February 2024 In Allies & Partnerships, Events, Melanoma Stories, Prevention, Science, Treatment

MRA’s 2024 Patient Forum brought together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education and promote collaboration.

Read More

Improving Communication With Your Melanoma Care Team

20 February 2024 In Allies & Partnerships, Events, Melanoma Stories, Treatment

Good communication is always challenging but can be especially so when you are undergoing treatment for melanoma. That’s because navigating our modern healthcare system is often an exercise in decoding complex jargon and knowing the right questions to ask while managing stress and other strong emotions.

Read More

Melanoma Research Alliance Applauds FDA Approval of First Cellular Therapy in Melanoma

16 February 2024 In Events, News, Treatment

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to approve Iovance Biotherapeutics’ AMTAGVITM (lifileucel) for the treatment of patients with advanced melanoma in the second line treatment setting.

Read More

Melanoma Immunotherapies & Immune-related Adverse Events: A Conversation with Dr. Alexandra-Chloé Villani

By Tanisha Jackson, PhD - MRA Scientific Program Director | 5 February 2024 In Allies & Partnerships, Events, Science, Treatment

Immune-related adverse events (irAEs) are side effects experienced by patients undergoing immunotherapy to treat their melanoma (or other cancer). In November, at the annual Society for Immunotherapy of Cancer (SITC) meeting, we spoke with Dr. Alexandra-Chloé Villani, an MRA-funded investigator at Massachusetts General Hospital, to learn more about immune-related adverse events and the research she leads in this area.

Read More

100,000 Americans Estimated to be Diagnosed with Invasive Melanoma in 2024

By Joan Levy, PhD - MRA Chief Science Officer | 26 January 2024 In News, Prevention, Science, Treatment

Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for...

Read More